DECLARE TIMI 58
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)
- Stadium
- klaar
- Middel
- dapagliflozin
- Populatie
- Diabetes Mellitus
- Fase
- III
- First Patient In
- 1 juni 2013
- Last Patient In
- 1 september 2014
- Last Patient Last Visit
- 11 juli 2018
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Studiedirecteur